Lupin's Somerset Facility Receives Positive FDA Review

Lupin Limited, a leader in the global pharmaceutical industry, announced today that its manufacturing site in Somerset, New Jersey, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA).

The facility underwent a rigorous inspection from May 7 to May 17, 2024, resulting in a Voluntary Action Indicated (VAI) status, which reflects satisfactory compliance with regulatory standards. Nilesh Gupta, Managing Director of Lupin, expressed satisfaction with the outcome, highlighting it as a testament to the company’s commitment to maintaining high standards in quality and compliance.